The current bidding competition for Oxford Glycosciences by Cambridge Antibody Technology and Cell...
The current bidding competition for Oxford Glycosciences by Cambridge Antibody Technology and Celltech is the most recent sign that things are looking up for biotechnology. Another came recently when I met a private client manager who wanted to discuss our fund because he had noticed that the Celltech share price had stopped going down. The support for biotechnology by some investors has been a combination of the biotech indices not revisiting their lows of July 2002 in the US and October 2002 in the UK. It also comes from the positive product, sales and profitability news c...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
